Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH (PERFORMA)
A Phase 3, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects With Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Phase 3, multicenter, multinational, 2-cohort, randomized, double-blind, placebo controlled, parallel-group pivotal study to evaluate the efficacy, safety, and clinical outcomes of pemvidutide treatment in subjects with noncirrhotic (F2 or F3) metabolic dysfunction-associated steatohepatitis (MASH). Participants will be assigned either to Cohort 1 based on screening histologic (liver biopsy) criteria or to Cohort 2 based on non-invasive test criteria.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Shaheen Tomah, MD
- Telefonnummer: 240-235-0145
- E-post: performa@altimmune.com
Studiesteder
-
-
Alabama
-
Dothan, Alabama, Forente stater, 36301
- Rekruttering
- Altimmune Clinical Study Site
-
-
Arizona
-
Chandler, Arizona, Forente stater, 85224
- Rekruttering
- Altimmune Clinical Study Site
-
Tucson, Arizona, Forente stater, 85712
- Rekruttering
- Altimmune Clinical Study Site
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72205
- Rekruttering
- Altimmune Clinical Study Site
-
North Little Rock, Arkansas, Forente stater, 72117
- Rekruttering
- Altimmune Clinical Study Site
-
-
California
-
Fountain Valley, California, Forente stater, 92708
- Rekruttering
- Altimmune Clinical Study Site
-
Fresno, California, Forente stater, 93720
- Rekruttering
- Altimmune Clinical Study Site
-
Gardena, California, Forente stater, 90247
- Rekruttering
- Altimmune Clinical Study Site
-
Huntington Park, California, Forente stater, 90255
- Rekruttering
- Altimmune Clinical Study Site
-
La Mesa, California, Forente stater, 91942
- Rekruttering
- Altimmune Clinical Study Site
-
Long Beach, California, Forente stater, 90815
- Rekruttering
- Altimmune Clinical Study Site
-
Orange, California, Forente stater, 92866
- Rekruttering
- Altimmune Clinical Study Site
-
Orange, California, Forente stater, 92868
- Rekruttering
- Altimmune Clinical Study Site
-
Poway, California, Forente stater, 92064
- Rekruttering
- Altimmune Clinical Study Site
-
Van Nuys, California, Forente stater, 91405
- Rekruttering
- Altimmune Clinical Study Site
-
-
Colorado
-
Englewood, Colorado, Forente stater, 80113
- Rekruttering
- Altimmune Clinical Study Site
-
-
Florida
-
Boca Raton, Florida, Forente stater, 33434
- Rekruttering
- Altimmune Clinical Study Site
-
Bradenton, Florida, Forente stater, 34209
- Rekruttering
- Altimmune Clinical Study Site
-
Miami, Florida, Forente stater, 33173
- Rekruttering
- Altimmune Clinical Study Site
-
Miami, Florida, Forente stater, 33122
- Rekruttering
- Altimmune Clinical Study Site
-
Miami Lakes, Florida, Forente stater, 33016
- Rekruttering
- Altimmune Clinical Study Site
-
Ocala, Florida, Forente stater, 34471
- Rekruttering
- Altimmune Clinical Study Site
-
Orlando, Florida, Forente stater, 32803
- Rekruttering
- Altimmune Clinical Study Site
-
Port Orange, Florida, Forente stater, 32127
- Rekruttering
- Altimmune Clinical Study Site
-
-
Georgia
-
Dalton, Georgia, Forente stater, 30720
- Rekruttering
- Altimmune Clinical Study Site
-
-
Indiana
-
South Bend, Indiana, Forente stater, 46635
- Rekruttering
- Altimmune Clinical Study Site
-
-
Louisiana
-
Bastrop, Louisiana, Forente stater, 71220
- Rekruttering
- Altimmune Clinical Study Site
-
Marrero, Louisiana, Forente stater, 70072
- Rekruttering
- Altimmune Clinical Study Site
-
Monroe, Louisiana, Forente stater, 71201
- Rekruttering
- Altimmune Clinical Study Site
-
-
Maryland
-
Laurel, Maryland, Forente stater, 20708
- Rekruttering
- Altimmune Clinical Study Site
-
-
Massachusetts
-
New Bedford, Massachusetts, Forente stater, 02740
- Rekruttering
- Altimmune Clinical Study Site
-
-
Missouri
-
Columbia, Missouri, Forente stater, 65201
- Rekruttering
- Altimmune Clinical Study Site
-
Kansas City, Missouri, Forente stater, 64131
- Rekruttering
- Altimmune Clinical Study Site
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87107
- Rekruttering
- Altimmune Clinical Study Site
-
-
North Carolina
-
Fayetteville, North Carolina, Forente stater, 28304
- Rekruttering
- Altimmune Clinical Study Site
-
-
Ohio
-
Brooklyn, Ohio, Forente stater, 44144
- Rekruttering
- Altimmune Clinical Study Site
-
Springboro, Ohio, Forente stater, 45066
- Rekruttering
- Altimmune Clinical Study Site
-
Westlake, Ohio, Forente stater, 44145
- Rekruttering
- Altimmune Clinical Study Site
-
-
Rhode Island
-
East Greenwich, Rhode Island, Forente stater, 02818
- Rekruttering
- Altimmune Clinical Study Site
-
-
Texas
-
Austin, Texas, Forente stater, 78757
- Rekruttering
- Altimmune Clinical Study Site
-
Bellaire, Texas, Forente stater, 77401
- Rekruttering
- Altimmune Clinical Study Site
-
Brownsville, Texas, Forente stater, 78520
- Rekruttering
- Altimmune Clinical Study Site
-
Corpus Christi, Texas, Forente stater, 78404
- Rekruttering
- Altimmune Clinical Study Site
-
Dallas, Texas, Forente stater, 75230
- Rekruttering
- Altimmune Clinical Study Site
-
Edinburg, Texas, Forente stater, 78539
- Rekruttering
- Altimmune Clinical Study Site
-
Farmers Branch, Texas, Forente stater, 75234
- Rekruttering
- Altimmune Clinical Study Site
-
Forney, Texas, Forente stater, 75126
- Rekruttering
- Altimmune Clinical Study Site
-
Fort Worth, Texas, Forente stater, 76104
- Rekruttering
- Altimmune Clinical Study Site
-
Georgetown, Texas, Forente stater, 78626
- Rekruttering
- Altimmune Clinical Study Site
-
Houston, Texas, Forente stater, 77004
- Rekruttering
- Altimmune Clinical Study Site
-
Houston, Texas, Forente stater, 77079
- Rekruttering
- Altimmune Clinical Study Site
-
Kingwood, Texas, Forente stater, 77339
- Rekruttering
- Altimmune Clinical Study Site
-
Pasadena, Texas, Forente stater, 77505
- Rekruttering
- Altimmune Clinical Study Site
-
San Antonio, Texas, Forente stater, 78215
- Rekruttering
- Altimmune Clinical Study Site
-
San Antonio, Texas, Forente stater, 78209
- Rekruttering
- Altimmune Clinical Study Site
-
San Antonio, Texas, Forente stater, 78229
- Rekruttering
- Altimmune Clinical Study Site
-
Sugar Land, Texas, Forente stater, 77479
- Rekruttering
- Altimmune Clinical Study Site
-
Waco, Texas, Forente stater, 76710
- Rekruttering
- Altimmune Clinical Study Site
-
-
Utah
-
Ogden, Utah, Forente stater, 84405
- Rekruttering
- Altimmune Clinical Study Site
-
West Jordan, Utah, Forente stater, 84088
- Rekruttering
- Altimmune Clinical Study Site
-
-
Washington
-
Seattle, Washington, Forente stater, 98105
- Rekruttering
- Altimmune Clinical Study Site
-
-
-
-
Puerto Rico
-
San Juan, Puerto Rico, Puerto Rico, 00927
- Rekruttering
- Altimmune Clinical Study Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
All subjects:
- No significant changes in body weight (±5%) and not participating in a structured weight loss program for the 3 months prior to screening (or since the historical biopsy, if applicable)
- Body mass index (BMI) ≥ 25.0 kg/m2; if Asian, BMI ≥ 23.0 kg/m2
- Type 2 diabetes (T2D) or at least 2 components of metabolic syndrome
- Subject agrees to have liver biopsy(ies) as required per protocol
Cohort 1 - Histologic diagnosis of F2/F3 MASH based on liver biopsy during screening or historical biopsy within 6 months before screening
Cohort 2 - Presumed F2/F3 MASH based on noninvasive testing
Exclusion Criteria:
- Cirrhosis (F4); portal hypertension or hepatic decompensation; acute or chronic liver disease other than MASH; liver function tests (ALT, AST; alkaline phosphatase; total bilirubin; INR; and platelet count) outside of acceptable ranges; positive HBsAg; active hepatitis C
- Uncontrolled T2D or clinically significant persistent hyperglycemia
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Placebo komparator: Placebo
|
Placebo SC Injection |
|
Eksperimentell: Pemvidutid 2,4 mg
|
Pemvidutide SC Injection |
|
Eksperimentell: Pemvidutide 1.8 mg
|
Pemvidutide SC Injection |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinical Outcome Event
Tidsramme: Baseline through end of study (approximately Month 60)
|
Time to first occurrence of any of the following events through the end of the study: Histologic progression to cirrhosis (F4) on liver biopsy; Liver related events; Liver transplantation; or Death due to any cause |
Baseline through end of study (approximately Month 60)
|
|
Histological Response: MASH resolution
Tidsramme: Baseline through Week 52
|
Proportion of subjects achieving MASH resolution (according to NASH Clinical Research Network [CRN] classification) without worsening of fibrosis |
Baseline through Week 52
|
|
Histological Response: Fibrosis improvement
Tidsramme: Baseline through Week 52
|
Proportion of subjects achieving ≥ 1 stage improvement in liver fibrosis according to the NASH CRN fibrosis staging system without worsening of MASH |
Baseline through Week 52
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Histologic Response: Proportion of subjects achieving both MASH resolution (according to NASH CRN classification) without worsening of fibrosis and ≥ 1 stage improvement in liver fibrosis without worsening of MASH
Tidsramme: Baseline through Week 52
|
Baseline through Week 52
|
|
HistoIndex qFibrosis: Proportion of subjects with at least a 1 stage improvement in qFibrosis
Tidsramme: Baseline through Week 52
|
Baseline through Week 52
|
|
Anthropometric parameters: Relative (%) change from baseline in body weight (kg)
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Anthropometric parameters: Relative (%) change from baseline in body mass index (BMI; kg/m2)
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Anthropometric parameters: Relative (%) change from baseline in waist circumference (cm)
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Absolute change from baseline in alanine aminotransferase (ALT; U/L)
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Absolute change from baseline in enhanced liver fibrosis (ELF) score
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Relative (%) change from baseline in vibration controlled transient elastography (VCTE; kPa) by Fibroscan
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
HRQoL: Change from baseline in core symptoms of MASH on the NASH-CHECK questionnaire.
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
HRQoL: Change from baseline in Short-form 36 (SF-36) summary scores.
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
HRQoL: Change from baseline in Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis (CLDQ-NASH) domain scores.
Tidsramme: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
Andre studie-ID-numre
- ALT-801-301
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .